1Y Annualised Return
▼-48.62%
3Y Annualised Return
▼-5.37%
5Y Annualised Return
▲18.36%
10Y Annualised Return
▲12.58%
Kopran Stock Performance
|
|
|
Kopran Company background
Founded in: 1958
Kopran Ltd., incorporated on April 26, 1958, was promoted by the Somani group and is controlled by Parijat Enterprises. The company came out with a public issue at a premium, in Nov.92, to finance its backward integration project to produce drug intermediates for semisynthetic drugs, and also to expand its antibiotic facility.Kopran manufactures pharmaceutical finished dosage forms and bulk drugs and distributes electronic equipment. It manufactures semisynthetic penicillin and is among the worlds highest producers in amoxycillin. Kopran also makes penicillinG acylase, an enzyme made through fermentation. It has technical collaborations with Gesellschaft Fur Biotechnologische, Germany Yuhan Corporation, South Korea Ciba Corning Diagnostic, US and Adac Laboratories, US.Koprans bulk drug plant has been approved by the US FDA and the UK regulatory authorities. In 1995, the company was awarded the Quality Excellence award by the Indian Drug Manufacturers Association. Koprans high growth rate in exports has been recognised by a number of awards from CHEMEXCIL and the Ministry of Commerce.The company launched new products like AZ1 Caps, Klodip Tabs, Moclox Kid Tabs, Amyn Kid Tabs, TiniNF, Amyn Caps and Amyn Dry Syrup. Kopran entered into a joint venture with M/s Industrial Promotion Services Ltd to take over a running unit viz Kampala Pharmaceuticals Industries Ltd in Uganda.The company has been ranked as amongst the top few fastest growing companies in India(ORG MargJune 2000). It closed down its manufacturing facility at Saki Naka, Andheri, Bombay. Globalpharma, a joint venture with Dubai Investments Corporation started commercial production in the first quarter of 2002.The company has increased its installed capacity of Liquids by 3.00 lakhs of Litres during 2001 and consequent of this capacity expansion the total installed capacity has gone up to 12.00 lakhs of Litres.The company has also increased its installed capacity of Tablets Capsules by 270 crores(Nos) and the total capacity has gone up to 1080 crores(Nos).In Feb. 2001, Kopran tied up with EMerck for comarketing a new antiinflammatory drug, Rofecoxib, in India. Rofecoxib is one of the fastmoving nonsteroid antiinflammatory drugs (NSAID),has been launched in the international market. The Company also launched Cholestat (Atorvastatin a cholesterol reducer) and further gave comarketing rights for Atorvastatin to EMerck (India). The company had launched new products in therapeutic groups like Asthma,Cardiology,Diabetes and Lifestyle products during 2003.The company has obtained approval from European Directorate for Quality of Medicines(EDQM) in September 2003. Upgradation of Formulation Manufacturing facility took place to meet with the latest International Regulatory Norms.The United Kingdom Medicines and Healthcare Products Regulatory Agency(UK MHRA) is expected to inspect the facilities in the first quarter of 2004.Kopran Pharmaceuticals Ltd., the Company marketing the SMYLE brand of products was merged into the Company effective from 1st March, 2005. The Company introduced two new bulk drugs viz. Pregabalin and Cefditorin during the year 2007. The Company during the FY 201415 sold the Active Pharmaceuticals Ingredients (API) business on slump sale basis to its subsidiary Kopran Research Laboratories Ltd. at a consideration of Rs 110 Crores on 30th March, 2015. Similarly, the Consumer Care Division was sold w.e.f 1 April 2015.
Kopran Financial Highlights
Kopran reported a Q1 FY 2025-26
revenue of ₹137.61 crore,
up 0.7% YoY,
with net profit decreased
-24.4% to ₹7.45 crore. For the full year FY2025–2026, revenue
reached ₹633.59 crore and profit touched at
₹38.55 crore.
As of 02 Sep, 2025, Kopran share price is ₹159.8. The stock opened at ₹160 and had closed at ₹158.3 the previous day. During today’s trading session, Kopran share price moved between ₹158.11 and ₹165.25, with an average price for the day of ₹161.68. Over the last 52 weeks, the stock has recorded a low of ₹154.06 and a high of ₹369.70. In terms of performance, Kopran share price has declined by 5% over the past six months and has declined by 48.62% over the last year.
Kopran SIP Return Calculator
Over the past
1 year
3 years
5 years
Total Investment of ₹65,00,000
Would have become ₹51,41,717 (-20.90%)
Daily SIP of ₹25,000 would have become ₹51,41,717 in 1 year with a gain of ₹-13,58,282 (-20.90%)
Kopran Fundamental
Market Cap (in crs)
771.65
Face Value
10
Turnover (in lacs)
991.79
Key Metrics
Qtr Change %
New 52W Low in past week
-12.7
Dividend yield 1yr %
0
Kopran Key Financials
Loading chart...
Loading chart...
Loading chart...
Loading chart...
Kopran Quarterly Revenue
| Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|
137.61 Cr | 175.45 Cr | 166.24 Cr | 151.56 Cr | 139.44 Cr |
Kopran Yearly Revenue
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|
633.59 Cr | 629.2 Cr | 554.05 Cr | 488.13 Cr | 509.8 Cr | 360.13 Cr |
Kopran Quarterly Net Profit/Loss
| Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|
7.45 Cr | 9.68 Cr | 10.4 Cr | 7.38 Cr | 11.1 Cr |
Kopran Yearly Net Profit/Loss
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|
38.55 Cr | 50.96 Cr | 27.23 Cr | 61.03 Cr | 61.61 Cr | 21.02 Cr |
Kopran Result Highlights
Result Summary
-
Kopran Ltd reported a 29.6% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 3.0%.
-
Its expenses for the quarter were down by 25.0% QoQ and up 0.4% YoY.
-
The net profit decreased 60.0% QoQ and decreased 32.9% YoY.
-
The earnings per share (EPS) of Kopran Ltd stood at 2 during Q1 FY 2025-26.
Data Source: BSE, Company announcements
The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.
Kopran Technical Analysis
Moving Averages Analysis
Moving Averages Analysis
159.81
Current Price
5Day EMA
158.10
10Day EMA
158.40
12Day EMA
158.70
20Day EMA
160.60
26Day EMA
162.30
50Day EMA
168.30
100Day EMA
177.40
200Day EMA
193.60
5Day SMA
157.20
10Day SMA
158.70
20Day SMA
158.90
30Day SMA
163.10
50Day SMA
170.30
100Day SMA
180.40
150Day SMA
179.70
200Day SMA
188.20
Delivery & Volume
| Period | Combined Delivery Volume | NSE+BSE Traded Volume |
|---|---|---|
Day Rs | 288086 Rs | 668813 Rs |
Week Rs | 108456 Rs | 240774 Rs |
Month Rs | 70068 Rs | 135940 Rs |
Resistance & Support
161.06
Pivot
Resistance
First Resistance
164.00
Second Resistance
168.20
Third Resistance
171.14
Support
First Support
156.86
Second support
153.92
Third Support
149.72
Relative Strength Index
44.35
Money Flow Index
73.62
MACD
-3.57
MACD Signal
-4.33
Average True Range
4.75
Average Directional Index
14.11
Rate of Change (21)
-0.81
Rate of Change (125)
-8
Kopran Peer comparison
| Index Name | Market Price | Market Cap | 52W Low | 52W High | Prev. Close | 1W Return | 1M Return | 6M Return | 1Y Return | 3Y Return | Dividend Yield | PE Ratio | Industry PE | PB Ratio |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
99.05 | 727.89 | 68.72 | 158.56 | 97.90 | 3.51% | -7.14% | 15.92% | -37.23% | 65.91% | 0.00% | 33.53 | 40.11 | 0.56 | |
86.51 | 867.04 | 74.25 | 122.85 | 87.17 | -1.01% | -9.79% | 13.49% | 0.00% | 0.00% | 0.87% | 18.75 | 40.11 | 2.65 | |
1,472.30 | 909.88 | 957 | 2374 | 1,473.50 | 3.17% | 12.13% | 42.65% | -31.28% | -7.67% | 0.12% | 49.95 | 40.11 | 3.21 | |
592.20 | 760.19 | 500 | 950 | 589.70 | 1.96% | 2.84% | -10.56% | -28.01% | 160.11% | 0.00% | 34.71 | 40.11 | 5.24 | |
336.90 | 749.60 | 210.1 | 380.8 | 332.40 | 1.49% | -1.75% | 36.12% | 3.39% | 52.89% | 0.00% | 37.85 | 40.11 | 2.52 | |
Accent Microcell Ltd. | - | 283.15 | - | - | - | - | - | - | - | - | - | - | - | - |
Kopran Share Price FAQs
What is Share Price of Kopran ?
Kopran share price is ₹159.81 in NSE and ₹159.35 in BSE as on 2/9/2025.
How has Kopran shares performed in the past ?
Kopran share price in the past 1-year return was -48.15. The Kopran share hit a 1-year low of Rs. 154.06 and a 1-year high of Rs. 369.7.
What is the market cap of Kopran ?
The market cap of Kopran is Rs. 771.65 Cr. as of 2/9/2025.
What is the current P/E ratio of Kopran ?
The PE ratios of Kopran is 29.45 as of 2/9/2025.
What is the current PB ratio of Kopran ?
The PB ratios of Kopran is 1.78 as of 2/9/2025
How to buy Kopran shares?
You can easily buy Kopran shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.
What is the 52-week high and low of Kopran ?
The 52-week high and low of Kopran share price is ₹369.7 and ₹154.06 as of 2/9/2025.
What is the EPS of Kopran ?
The earnings per share (EPS) of Kopran stood at 2 during Q1 FY 2025-26.
Please be aware that Kopran stock prices are subject to continuous fluctuations due to various factors.
Open Demat Account